Today: 10 June 2026
Browse Category

Health News 12 December 2025 - 24 January 2026

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly stock set for Tuesday spotlight as new obesity-pill data ripples through GLP-1 trade

Eli Lilly shares rose 0.5% to $1,038.40 Friday, ahead of a holiday-shortened week. Traders are watching early U.S. prescription numbers for Novo Nordisk’s new oral Wegovy, which logged 3,071 scripts in its debut, just below Lilly’s Zepbound. U.S. markets reopen Tuesday, with investors eyeing fresh demand signals and pricing risks. About 3.8 million Lilly shares traded Friday.
19 January 2026
···
Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

Why ImmunityBio stock is surging today: ANKTIVA sales jump and a key bladder-cancer trial nears the finish line

ImmunityBio shares jumped 16.5% to $4.60 Friday after the company reported $113 million in preliminary 2025 net product revenue from ANKTIVA and disclosed accelerated approvals in Saudi Arabia for lung and bladder cancer uses. Trading volume topped 56 million shares. Enrollment in the company’s pivotal bladder-cancer trial surpassed 85%, with FDA filing planned by late 2026.
16 January 2026
···
Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recall expands: Peace by Chocolate pistachio chocolates pulled over salmonella risk

Costco Canada recalled certain Peace by Chocolate gift boxes sold online after a supplier warned of possible Salmonella in two pistachio chocolates. The recall affects products bought on Costco.ca between Sept. 7 and Dec. 3, with no reported illnesses as of Jan. 8. Canada’s pistachio recall list now covers over 330 products. The CFIA says its investigation is ongoing and more recalls may follow.
9 January 2026
·
Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck (MRK) stock slips after-hours as CDC backs one-dose HPV shot; Cidara deal closes

Merck shares slipped 0.2% in after-hours trading after U.S. health officials cut HPV vaccine guidance to one dose, raising concerns over Gardasil sales. Analysts warned the change could reduce 2026 Gardasil revenue by up to $630 million. Merck also completed its $9.2 billion Cidara acquisition and set Feb. 3 for quarterly results.
8 January 2026
····
Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk (NVO) stock jumps as $149 Wegovy pill rollout puts pricing in the spotlight

Novo Nordisk’s U.S.-listed shares rose 4.7% to $57.71 Tuesday after launching oral Wegovy for self-pay patients at $149 a month for starter doses. The pill is now available at major pharmacies and through telehealth. Investors await early demand data and updates from a key healthcare conference on Jan. 13. Rival Eli Lilly expects a regulatory decision on its own weight-loss pill in March.
6 January 2026
···
Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk stock jumps premarket as $149 Wegovy pill hits U.S. market

Novo Nordisk’s U.S.-listed shares rose about 4% in premarket trading after the company launched an oral version of its Wegovy weight-loss drug, priced from $149 a month for some cash-paying patients. The stock traded at $57.29, up from $55.11. Investors are watching early demand and await the company’s February 4 results for margin outlook. The launch comes amid restructuring and job cuts at Novo’s U.S. operations.
6 January 2026
···
Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics shares fell 9.9% to $31.93 Monday after Novo Nordisk launched its Wegovy weight-loss pill in the U.S. with starter doses priced at $149 per month for cash-pay patients. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly dropped 3.9%. Viking’s next updates include Phase 3 trial milestones in Q1 and an earnings release expected Feb. 4.
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals shares fell 6.9% to $63.11 Monday after Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock dropped despite the clearance, tracking weakness across biotech stocks. Investors now await Arrowhead’s obesity data webinar on Jan. 6 and its J.P. Morgan conference presentation Jan. 12.
5 January 2026
···
Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics (GPCR) Stock News and Forecasts on Dec. 23, 2025: Oral Obesity Pipeline, Capital Raise, Analyst Targets, and What Comes Next

Structure Therapeutics shares traded near $67.50 on Dec. 23, 2025, following strong Phase 2 data for its oral obesity drug aleniglipron, which showed up to 15.3% placebo-adjusted weight loss at 36 weeks. The company also closed a $747.5 million public offering after the trial results.
23 December 2025
····
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

The FDA approved Novo Nordisk’s once-daily Wegovy pill (oral semaglutide 25 mg) for chronic weight management and reducing cardiovascular risk in adults with obesity or overweight on December 22, 2025. The company plans a U.S. launch in January 2026 at $149 per month for eligible patients. Clinical trials showed average weight loss of 13.6% to 16.6% depending on adherence.
23 December 2025
··
So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)

So Delicious Dairy Free Ice Cream Recall: Danone Pulls Salted Caramel Cluster Pints Over Possible “Small Stones” (Dec. 17, 2025)

Danone U.S. has recalled So Delicious Dairy Free Salted Caramel Cluster pints nationwide after small stones and other hard objects were found in cashew pieces, according to the FDA. The recall covers pints with UPC 744473476138 and best-by dates before Aug. 8, 2027. Major retailers, including Target, Whole Foods, and Walmart in Hawai‘i, have been affected. Other So Delicious flavors are not included.
18 December 2025
·
California Vega Farms Egg Recall: 63 Sick, 13 Hospitalized in Salmonella Outbreak—How to Identify Affected Eggs

California Vega Farms Egg Recall: 63 Sick, 13 Hospitalized in Salmonella Outbreak—How to Identify Affected Eggs

California health officials have linked 63 Salmonella illnesses and 13 hospitalizations to Vega Farms in-shell brown eggs, prompting a recall on Dec. 5. The eggs were sold in Sacramento and Davis through retail stores, restaurants, and farmers markets. Testing found Salmonella matching the outbreak strain in samples from Vega Farms. No deaths have been reported.
16 December 2025
McCain Pizza Pockets Recall Australia 2025: Cheese & Bacon 400g Pulled from Woolworths, Coles and IGA After Plastic and Metal Contamination Warning

McCain Pizza Pockets Recall Australia 2025: Cheese & Bacon 400g Pulled from Woolworths, Coles and IGA After Plastic and Metal Contamination Warning

McCain Foods has recalled McCain Cheese & Bacon Pizza Pockets 400g nationwide after reports of plastic found inside the product, with possible metal contamination also not ruled out. The recall affects batch code 1005481714 with best-before dates OCT 2026 A (289–291), sold at major supermarkets and online across Australia. Food authorities warn consumers not to eat the product and to return it for a refund.
12 December 2025
···
1 2 3 4

Stock Market Today

  • Stock Market Update June 9: Nasdaq Slumps Amid Tech Sell-Off and Risk-Off Sentiment
    June 9, 2026, 6:04 PM EDT. On June 9, the S&P 500 declined 0.26% to 7,386.65, and the Nasdaq Composite dropped 0.97% to 25,678.82, pressured by a renewed sell-off in technology and semiconductor stocks. Broadcom, Micron, AMD, and Intel led the losses, while Microsoft and Apple also fell despite new partnerships and AI capability concerns, respectively. The Dow Jones Industrial Average marginally rose 0.17% after a late recovery. Market volatility stemmed from profit-taking, risk reduction ahead of key U.S. inflation data, geopolitical tensions, and repositioning ahead of SpaceX's mega-IPO. Diversification is advised as investors shift away from tech to mitigate concentration risks. Meanwhile, The Motley Fool's Stock Advisor highlighted its top 10 growth stocks, excluding the S&P 500, emphasizing long-term investing opportunities.

Latest articles

Opendoor Faces Russell 3000 Deadline as Housing Market Remains Main Issue

Opendoor Faces Russell 3000 Deadline as Housing Market Remains Main Issue

9 June 2026
Opendoor shares rose 0.8% to $4.34 as investors positioned for its pending inclusion in the Russell 3000, set to take effect after June 26; index entry can boost demand from passive funds, but Opendoor’s Q1 revenue fell to $720 million with a wider $173 million net loss, and the company warned of risks from mortgage-rate volatility and housing market swings.
T1 Energy Stock Just Got Hit—KORE Deal Filing Puts Dilution Back in Focus

T1 Energy Stock Just Got Hit—KORE Deal Filing Puts Dilution Back in Focus

9 June 2026
T1 Energy shares plunged 7.4% to $8.46 after a new filing revealed details on stock-based payments for the KORE Power acquisition, raising dilution concerns as the deal’s share count will be set by a 10-day VWAP; a lower VWAP could mean more shares issued, pressuring existing holders amid sector-wide weakness and ongoing risks to closing and financing.
Navitas Tumbles as $500 Million Stock Sale Interrupts Nvidia Surge

Navitas Tumbles as $500 Million Stock Sale Interrupts Nvidia Surge

9 June 2026
Navitas Semiconductor shares plunged 6.6% to $22.85 after unveiling a $500 million stock-sale program, a board resignation, and weaker chip sector sentiment, as investors weighed dilution risks and uncertainty around AI-infrastructure demand despite a new product launch and recent ties to Nvidia’s MGX ecosystem.
Epsium Enterprise Shares Surge 72% in Volatile Nasdaq Trading

Epsium Enterprise Shares Surge 72% in Volatile Nasdaq Trading

9 June 2026
Epsium Enterprise soared 72.27% to close at $2.05 on record volume over 65 million shares—more than 200 times its average—before dropping 18.54% after hours to $1.67, as traders piled into the volatile Macau beverage wholesaler despite no major news and fundamentals showing falling revenue and a net loss.
Go toTop